Acurx Pharmaceuticals
ACXP
10 hedge funds and large institutions have $455K invested in Acurx Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 1 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
37% more capital invested
Capital invested by funds: $332K → $455K (+$123K)
25% more funds holding
Funds holding: 8 → 10 (+2)
0.02% more ownership
Funds ownership: 0.03% → 0.05% (+0.02%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$68.3K |
| 2 |
TAM
Tocqueville Asset Management
New York
|
+$28.5K |
| 3 |
PFGIA
Patriot Financial Group Insurance Agency
Westborough,
Massachusetts
|
+$14.3K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$9.51K |
| 5 |
BlackRock
New York
|
+$761 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$76.9K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TWC
1
TD Waterhouse Canada
Toronto,
Ontario, Canada
| $138K | +$143K | +1,500 | New |
|
|
TAM
2
Tocqueville Asset Management
New York
| $108K | +$28.5K | +300 | +31% |
|
|
HF
3
HRT Financial
New York
| $62K | +$68.3K | +718 | New |
|
|
4
Millennium Management
New York
| $61K | -$76.9K | -808 | -54% |
|
|
PFGIA
5
Patriot Financial Group Insurance Agency
Westborough,
Massachusetts
| $30K | +$14.3K | +150 | +75% |
|
|
6
BlackRock
New York
| $29K | +$761 | +8 | +2% |
|
|
7
Osaic Holdings
Scottsdale,
Arizona
| $22K | +$9.51K | +100 | +67% |
|
|
SFA
8
Semmax Financial Advisors
Winston Salem,
North Carolina
| $5K | – | – | – |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| – | -$4K | -35 | Closed |
|
10
Bank of America
Charlotte,
North Carolina
| – | +$476 | +5 | New |
|
ACXP Hedge Fund Activity: Q4 2021 in Review
10 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Acurx Pharmaceuticals (ACXP) for Q4 2021, worth a combined $455K — up 37% from $332K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ACXP positions and 1 closed out — a net gain of 2 holders — while 4 added to existing stakes and 1 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $68.3K. The largest seller was Millennium Management, cutting an estimated $76.9K.
- 10 institutional investors held Acurx Pharmaceuticals (ACXP) as of Q4 2021, up from 8 in Q3 2021.
- Funds reported $455K of Acurx Pharmaceuticals stock for Q4 2021, up 37% quarter-over-quarter.
- 3 funds opened new Acurx Pharmaceuticals positions in Q4 2021 and 1 closed out, a net change of +2 holders.
- The largest Acurx Pharmaceuticals buyer in Q4 2021 was HRT Financial, an estimated $68.3K added.
- The largest Acurx Pharmaceuticals seller in Q4 2021 was Millennium Management, an estimated $76.9K sold.
Based on aggregated 13F filings for Q4 2021.